Robbins LLP is Investigating Allegations that Grail, Inc. (GRAL) Misled Investors Concerning the Success of its NHS-Galleri Trial

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. Grail, Inc. describes itself as a commercial stage healthcare company with a focus on early cancer detection through screening methodology.

The Allegations

According to the complaint, during the class period, defendants misled investors regarding the true probability of success the NHS-Galleri study had in achieving its primary endpoint of a statistically significant reduction in Stage III & IV cancers. Defendants’ statements included, among other things, confidence in the success of Galleri, consistently promoting its effectiveness “in the real world” and the positive predictive value (“PPV”) observed in the Pathfinder studies and in NHS-Galleri’s top-line results as sources of confidence for its potential.

Plaintiff alleges that on February 19, 2026, defendants reported that the "Landmark NHS-Galleri Trial" failed to achieve its primary endpoint. On this news, Grail's stock price fell from $101.53 per share on February 19, 2026, to $50.21 per share on February 20, 2026, a decline of approximately 50.55% in a single trading day.

What Now: You may be eligible to participate in the class action against Grail, Inc. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.